Charles River Laboratories | CRL - Current Assets


Charles River Laboratories reported $1.54B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Agilent USD 4.69B 70M Jun/2026
Align Technology USD 2.73B 63.03M Sep/2026
Bio-Rad Laboratories USD 3.08B 58.1M Sep/2026
Bruker USD 2.16B 67.9M Sep/2026
Cardinal Health USD 40.99B 2.24B Sep/2026
Charles River Laboratories USD 1.54B 5.92M Sep/2026
Cigna USD 47.23B 241M Sep/2026
Concord Medical Services Hldg CNY 941.91M 83.42M Dec/2025
CVS Health USD 79.39B 4.05B Sep/2026
Danaher USD 14.79B 1.41B Sep/2026
Dentsply International USD 1.98B 50M Sep/2026
Elevance Health USD 68.52B 1.34B Sep/2026
Humana USD 39.61B 477M Sep/2026
Illumina USD 3.04B 201M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
IQVIA Holdings USD 6.45B 225M Sep/2026
Laboratory Of America USD 3.97B 151.3M Sep/2026
Lakefront Biotherapeutics EUR 2.31B 751.38M Jun/2026
Lonza CHF 8B 3.41B Dec/2025
McKesson USD 66.68B 3.85B Sep/2026
Merck EUR 15.14B 1.37B Sep/2026
Mettler Toledo International USD 1.38B 28.79M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Quest Diagnostics USD 3.12B 273M Sep/2026
Revvity USD 1.86B 436.33M Sep/2026
Thermo Fisher Scientific USD 25.62B 2.25B Sep/2026
United Therapeutics USD 2.88B 603.5M Sep/2026
UnitedHealth USD 85.6B 1.27B Sep/2026
Veradigm USD 679.65M 131.12M Dec/2022
Waters USD 3.9B 186M Jun/2026
West Pharmaceutical Services USD 1.82B 9M Sep/2026